TY - JOUR
T1 - Immunosignature differentiation of non-infectious meningoencephalomyelitis and intracranial neoplasia in dogs
AU - Lake, Bathilda B.
AU - Rossmeisl, John Henry
AU - Cecere, Julie
AU - Stafford, Phillip
AU - Zimmerman, Kurt L.
N1 - Funding Information:
The authors would like to acknowledge the Canine Central Nervous System Tumor Biorepository for intracranial neoplasia case serum samples, maintained by JR. The authors received financial support from the Veterinary Memorial Fund 444163, NIH/NCI P01CA207206 and NIH/NCI R01CA139099 and The Peptide Array Core at the Biodesign Institute, Arizona State University.
Publisher Copyright:
© 2018 Lake, Rossmeisl, Cecere, Stafford and Zimmerman.
PY - 2018/5/11
Y1 - 2018/5/11
N2 - A variety of inflammatory conditions of unknown cause (meningoencephalomyelitis of unknown etiology-MUE) and neoplastic diseases can affect the central nervous system (CNS) of dogs. MUE can mimic intracranial neoplasia both clinically, radiologically and even in some cases, histologically. Serum immunosignature protein microarray assays have been used in humans to identify CNS diseases such as Alzheimer's and neoplasia, and in dogs, to detect lymphoma and its progression. This study evaluated the effectiveness of immunosignature profiles for distinguishing between three cohorts of dogs: healthy, intracranial neoplasia, and MUE. Using the learned peptide patterns for these three cohorts, classification prediction was evaluated for the same groups using a 10-fold cross validation methodology. Accuracy for classification was 100%, as well as 100% specific and 100% sensitive. This pilot study demonstrates that immunosignature profiles may help serve as a minimally invasive tool to distinguish between MUE and intracranial neoplasia in dogs.
AB - A variety of inflammatory conditions of unknown cause (meningoencephalomyelitis of unknown etiology-MUE) and neoplastic diseases can affect the central nervous system (CNS) of dogs. MUE can mimic intracranial neoplasia both clinically, radiologically and even in some cases, histologically. Serum immunosignature protein microarray assays have been used in humans to identify CNS diseases such as Alzheimer's and neoplasia, and in dogs, to detect lymphoma and its progression. This study evaluated the effectiveness of immunosignature profiles for distinguishing between three cohorts of dogs: healthy, intracranial neoplasia, and MUE. Using the learned peptide patterns for these three cohorts, classification prediction was evaluated for the same groups using a 10-fold cross validation methodology. Accuracy for classification was 100%, as well as 100% specific and 100% sensitive. This pilot study demonstrates that immunosignature profiles may help serve as a minimally invasive tool to distinguish between MUE and intracranial neoplasia in dogs.
KW - Canine
KW - Immunosignature
KW - Intracranial neoplasia
KW - Meningoencephalomyelitis of unknown etiology
KW - Peptide microarray
UR - http://www.scopus.com/inward/record.url?scp=85046847185&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85046847185&partnerID=8YFLogxK
U2 - 10.3389/fvets.2018.00097
DO - 10.3389/fvets.2018.00097
M3 - Article
AN - SCOPUS:85046847185
SN - 2297-1769
VL - 5
JO - Frontiers in Veterinary Science
JF - Frontiers in Veterinary Science
IS - MAY
M1 - 97
ER -